PLT012 Mechanism of Action

PLT012 is a humanized anti-CD36 antibody with a dual mechanism of action. It simultaneously inhibits immunosuppressive cell populations and enhances effector T cell function. Preclinical studies as monotherapy have demonstrated its efficacy in both immune-hot and immune -cold tumor models, with a significant increase in GzmB-expressing CD8+ T cells and reductions in intratumoral Tregs and pro-tumorigenic macrophages. Additionally, PLT012 reshapes the exhaustion profile of cytotoxic CD8+ T cells by expanding both progenitor-exhausted (Tex^prog) and terminally-exhausted (Tex^term) populations with rejuvenated effector functions, leading to enhanced tumoricidal immunity. These findings suggest that PLT012, functioning as a metabolic regulator, may provide therapeutic benefits in cancer treatment, either as a monotherapy or in combination with immune checkpoint inhibitors such as PD-1 or PD-L1 inhibitors. Other than oncology, the unique MOA as a metabolic regulator also shows the potential of reprogramming the metabolic environment with associated benefits, e.g. liver functional improvement, thus laying the groundwork for targeting a broader spectrum of metabolic and immunological diseases.